We compared neoadjuvant PD-1 inhibitor plus S-1+oxaliplatin (SOX) versus PD-1 inhibitor plus 5-FU+oxaliplatin+Docetaxel+Leucovorin (FLOT) in a real-world cohort.<h4>Methods</h4>This single-center retrospective study included patients with resectable, HER2-negative LAGC/EGJ adenocarcinoma (cT3-4b, any N+, M0; ECOG 0-1) treated between July 2020 and July 2025. The gene discussed is ERBB2; the disease is adenocarcinoma.